Cited by 214Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Peripheral immune system in aging and Alzheimer’s disease

Open access
Cao, Wei, Zheng, Hui·2018·Molecular Neurodegeneration

Abstract

Alzheimer's disease (AD) represents an urgent public health mandate. AD is no longer considered a neural-centric disease; rather, a plethora of recent studies strongly implicate a critical role played by neuroinflammation in the pathogeneses of AD and other neurodegenerative conditions. A close functional connection between the immune system and central nervous system is increasingly recognized. In late-onset AD, aging represents the most significant risk factor. Here, from an immunological perspective, we summarize the prominent molecular and cellular changes in the periphery of aging individuals and AD patients. Moreover, we review the knowledge gained in the past several years that implicate specific arms of the peripheral immune system and other types of immune responses in modulating AD progression. Taken together, these findings collectively emphasize a dynamic role of a concert of brain-extrinsic, peripheral signals in the aging and degenerative processes in the CNS. We believe that a systematic view synthesizing the vast amounts of existing results will help guide the development of next-generation therapeutics and inform future directions of AD investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-018-0284-2

Cites

199 of 199 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 8

  1. [52]Walker RG Poggioli T Katsimpardi L Buchanan SM Oh J Wattrus S Heidecker B Fong YW Rubin LL Ganz P Thompson TB Wagers AJ Lee RT Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation Circ Res 2016 118 1125 1141 10.1161/CIRCRESAHA.116.308391 27034275 PMC4818972 · DOI
  2. [104]Wang YJ Alzheimer disease: Lessons from immunotherapy for Alzheimer disease Nat Rev Neurol 2014 10 188 189 10.1038/nrneurol.2014.44 24638135 · DOI
  3. [120]Monsonego A Zota V Karni A Krieger JI Bar-Or A Bitan G Budson AE Sperling R Selkoe DJ Weiner HL Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease J Clin Invest 2003 112 415 422 10.1172/JCI200318104 12897209 PMC166296 · DOI · Paper page
  4. [121]Loewenbrueck KF Tigno-Aranjuez JT Boehm BO Lehmann PV Tary-Lehmann M Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease Neurobiol Aging 2010 31 1732 1742 10.1016/j.neurobiolaging.2008.09.007 19058879 · DOI
  5. [131]Alves S Churlaud G Audrain M Michaelsen-Preusse K Fol R Souchet B Braudeau J Korte M Klatzmann D Cartier N Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice Brain 2017 140 826 842 10.1093/brain/awx109 28003243 · DOI
  6. [183]Butchart J Brook L Hopkins V Teeling J Puntener U Culliford D Sharples R Sharif S McFarlane B Raybould R Thomas R Passmore P Perry VH Holmes C Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial Neurology 2015 84 2161 2168 10.1212/WNL.0000000000001617 25934853 PMC4451045 · DOI
  7. [186]Potter H, Woodcock JH, Boyd T, Sillau SH, Bettcher BM, Daniels J, Heffernan K, Gray H. Safety and Efficacy Results from Phase 2 pilot trial of GM-CSF/Leukine® in mild-tomoderate AD. AAIC. 2017;2017:P38.
  8. [197]Sheean RK McKay FC Cretney E Bye CR Perera ND Tomas D Weston RA Scheller KJ Djouma E Menon P Schibeci SD Marmash N Yerbury JJ Nutt SL Booth DR Stewart GJ Kiernan MC Vucic S Turner BJ Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model JAMA Neurol 2018 75 681 689 10.1001/jamaneurol.2018.0035 29507931 PMC5885208 · DOI

Cited by

Sorted by citations

Authors
Cao, W., & Zheng, H.
Affiliations
Baylor College of Medicine (US)
Corresponding author
  • Cao, Wei
  • Zheng, Hui
Venue
Molecular Neurodegeneration
Published
2018-10-03
Volume
13
Issue
1
Pages
51-51
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2894696369
Cited by
214
References
199
Citations by year
2026: 14 · 2025: 18 · 2024: 30 · 2023: 34 · 2022: 34 · 2021: 30 · 2020: 33 · 2019: 19 · 2018: 2
FWCI
1.99
Type
journal article
Language
en
Open access
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (AG020670)
  • National Institute on Aging (RF1AG054111, RF1AG057587, RF1AG020670, R01AG032051, R01AG020670)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, aging, peripheral immune system, neuroinflammation, neurodegeneration, late-onset Alzheimer's disease, immunomodulation
MeSH terms
Aging, Alzheimer Disease, Animals, Behavior, Central Nervous System, Disease Models, Animal, Humans, Immune System

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review